A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

Clinical trial NCT04155515 · COMPLETED

Trial details

NCT number: NCT04155515
Sponsor: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Hepatics C Virus (HCV) Genotype 1 Non-Cirrhotic Cirrhosis Treatment naïve

Start date: 2019-06-13
Primary completion: 2020-08-11
Enrollment: 370

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.